Akebia Therapeutics Inc's Customers Performance

Name: Akebia Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

AKBA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


AKBA's Source of Revenues		During the corresponding time, Akebia Therapeutics Inc saw a revenue deteriorated by -21.36 % year on year, sequentially revenue fell by -8.25 %. While revenue at the Akebia Therapeutics Inc 's corporate clients • List of AKBA Customers

for the same period Akebia Therapeutics Inc revnue deteriorated by -21.36 % year on year, sequentially revenue fell by -8.25 %.

• List of AKBA Customers

Akebia Therapeutics Inc's Business Units


Product	201.02 %	of total Revenue
License, collaboration and other revenue	7.97 %	of total Revenue
Vafseo	75.53 %	of total Revenue
Auryxia	125.49 %	of total Revenue
JT and Torii Sublicense Agreement	1.63 %	of total Revenue
Reportable	208.99 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Akebia Therapeutics Inc's Comment on Sales, Marketing and Customers

The company operates in the manufacture and supply of pharmaceutical products, including Vafseo, vadadustat, and Auryxia. It relies on suppliers and contract manufacturing organizations (CMOs) for clinical and commercial supply. Supply agreements for Vafseo are in place with STA Pharmaceutical Hong Kong Limited and Patheon Inc. For Auryxia, the drug substance is supplied by Siegfried Evionnaz SA, and the drug product is supplied by Patheon Manufacturing Services LLC (Thermo Fisher). The company also provides authorized generic supply for Auryxia. The synthesis and formulation processes for vadadustat and Auryxia are described as reliable and reproducible at commercial scale, utilizing proprietary manufacturing methods. Supply risks are managed through inventory control and potential additional manufacturing arrangements.

Akebia Therapeutics Inc’s Comment on Sales, Marketing and Customers

AKBA's Stock Performance relative to it's Customers

AKBA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Akebia Therapeutics Inc	270.95	232.40	-20.51	194
SUBTOTAL	0.00	0.00	0.00	-

Sources: Akebia Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Akebia Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Akebia Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.